97 related articles for article (PubMed ID: 30381967)
1. A novel PI3K/mTOR dual inhibitor XH002 exhibited robust antitumor activity in NSCLC.
Lv Y; Du T; Ji M; Wang C; Lin S; Xue N; Jin J; Xu H; Chen X
J Drug Target; 2019 Apr; 27(4):451-459. PubMed ID: 30381967
[TBL] [Abstract][Full Text] [Related]
2. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
3. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
4. A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer.
Zhang Q; Zhang Y; Chen Y; Qian J; Zhang X; Yu K
Clin Cancer Res; 2019 Jun; 25(12):3630-3642. PubMed ID: 30796032
[TBL] [Abstract][Full Text] [Related]
5. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
Yuan J; Mehta PP; Yin MJ; Sun S; Zou A; Chen J; Rafidi K; Feng Z; Nickel J; Engebretsen J; Hallin J; Blasina A; Zhang E; Nguyen L; Sun M; Vogt PK; McHarg A; Cheng H; Christensen JG; Kan JL; Bagrodia S
Mol Cancer Ther; 2011 Nov; 10(11):2189-99. PubMed ID: 21750219
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
[TBL] [Abstract][Full Text] [Related]
7. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
Zheng R; Jiang H; Li J; Liu X; Xu H
Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
9. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
10. P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
Venkatesha VA; Joshi A; Venkataraman M; Sonawane V; Bhatia D; Tannu P; Bose J; Choudhari S; Srivastava A; Pandey PK; Lad VJ; Sangana R; Ahmed T; Damre A; Deore V; Sahu B; Kumar S; Sharma S; Agarwal VR
Mol Cancer; 2014 Dec; 13():259. PubMed ID: 25466244
[TBL] [Abstract][Full Text] [Related]
11. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
12. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
Sun Z; Wang Z; Liu X; Wang D
Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
[TBL] [Abstract][Full Text] [Related]
13. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
14. Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.
Piao J; Chen L; Quan T; Li L; Quan C; Piao Y; Jin T; Lin Z
Oncotarget; 2016 Sep; 7(37):60169-60180. PubMed ID: 27507059
[TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.
Mallon R; Feldberg LR; Lucas J; Chaudhary I; Dehnhardt C; Santos ED; Chen Z; dos Santos O; Ayral-Kaloustian S; Venkatesan A; Hollander I
Clin Cancer Res; 2011 May; 17(10):3193-203. PubMed ID: 21325073
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
[TBL] [Abstract][Full Text] [Related]
17. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
[No Abstract] [Full Text] [Related]
18. Novel ROR1 inhibitor ARI-1 suppresses the development of non-small cell lung cancer.
Liu X; Pu W; He H; Fan X; Zheng Y; Zhou JK; Ma R; He J; Zheng Y; Wu K; Zhao Y; Yang SY; Wang C; Wei YQ; Wei XW; Peng Y
Cancer Lett; 2019 Aug; 458():76-85. PubMed ID: 31125641
[TBL] [Abstract][Full Text] [Related]
19. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
